Gastrointestinal Microbiome Study of Appendiceal Cancer
Pseudomyxoma Peritonei, Appendiceal Neoplasm, Cancer, Appendiceal
About this trial
This is an interventional other trial for Pseudomyxoma Peritonei focused on measuring cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, microbiome
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of appendiceal cancer with peritoneal spread
- Candidate for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC)
- ≥18 and ≤ 80 years of age
- Eastern Cooperative Oncology Group performance status score of ≤2/Karnofsky performance status (KPS) ≥70%
- Signed Institutional Review Board approved informed consent
Exclusion Criteria:
- <18 years of age
- Pregnant women
- Concurrent severe medical problems unrelated to malignancy
Sites / Locations
- Mercy Medical CenterRecruiting
Arms of the Study
Arm 1
Other
Microbiome cohort
Pre-operative (baseline) bio-specimen collection (fecal sample) and completion of two food and lifestyle questionnaires. Six to twelve weeks following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), post-operative bio-specimen collection (fecal sample) and completion of two food and lifestyle questionnaires Six to twelve months following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), post-operative bio-specimen collection (fecal sample) and completion of two food and lifestyle questionnaires